One primary goal of therapy for patients with acute coronary syndrome (ACS) is restoring blood flow to the heart muscle as quickly as possible. This is called reperfusion, and every minute it’s delayed, more heart tissue dies. But reperfusion is just one piece of a larger treatment strategy that includes relieving pain, preventing blood clots from growing, protecting the heart from further damage, and reducing the risk of a second event.
Why Restoring Blood Flow Comes First
ACS happens when a coronary artery becomes partially or fully blocked, usually by a blood clot forming on a ruptured plaque. The heart muscle downstream of that blockage starts to starve for oxygen. In the most severe form, called STEMI, the artery is completely blocked and the damage spreads rapidly. The 2025 ACC/AHA guidelines make the priority clear: rapid reperfusion of the blocked artery is associated with improved salvage of heart muscle and improved survival.
For STEMI patients, guidelines recommend that the time from hospital arrival to reopening the artery should be 90 minutes or less. This is sometimes called “door-to-balloon time” because it measures how quickly a catheter with a tiny balloon can reach the blockage and inflate to restore flow. When that procedure isn’t available quickly enough, clot-dissolving medications serve as a backup. In either case, nothing should delay the effort to get blood moving again.
For the other forms of ACS (NSTEMI and unstable angina), the blockage is usually partial, so the timeline is slightly less urgent but still pressing. Patients at intermediate or high risk of further damage are recommended to undergo catheterization during their hospitalization. Those who are unstable, with ongoing chest pain, dangerous heart rhythms, or signs of heart failure, should be taken to the catheterization lab within two hours of admission.
How the Three Types of ACS Differ
ACS is an umbrella term covering three conditions. STEMI shows a characteristic pattern on an EKG where the ST segment is elevated, signaling a complete arterial blockage. NSTEMI does not show that EKG pattern but does produce elevated troponin, a protein that leaks into the blood when heart cells are injured. Unstable angina looks similar to NSTEMI but troponin levels stay normal, meaning the heart is in danger but hasn’t yet sustained measurable damage. Troponin, measured with a simple blood test, is the key biomarker that separates NSTEMI from unstable angina.
Relieving Pain and Reducing Heart Strain
Pain control isn’t just about comfort. When you’re in severe pain, your body floods with stress hormones that speed up the heart rate and raise blood pressure. Both of those responses force the heart to work harder and demand more oxygen, which is exactly what a struggling heart can’t afford. The 2025 guidelines describe rapid and effective pain relief as an important treatment goal specifically to prevent this stress response and the complications it causes.
Nitroglycerin is one of the first medications given because it widens blood vessels, easing the heart’s workload and improving blood flow. However, it’s not safe for everyone. It should be avoided in patients with very low blood pressure (below 90 mmHg), those who have taken erectile dysfunction medications like sildenafil within the prior 24 to 48 hours, and those with a type of heart attack affecting the right side of the heart. In that last scenario, the heart depends heavily on blood volume returning to it, and nitroglycerin’s vessel-widening effect can cause a dangerous drop in blood pressure.
Preventing the Clot From Growing
Even after the initial blockage is addressed, the clot that caused the problem can keep expanding or new clots can form. Aspirin is given as early as possible to prevent platelets from clumping together. Research published in Annals of Emergency Medicine found that giving aspirin within one hour of arriving at the emergency department was the single strongest predictor of surviving the next 30 days, with roughly 65% lower odds of death compared to patients who received it later. A second antiplatelet medication is typically added on top of aspirin to provide stronger protection, a combination known as dual antiplatelet therapy.
Protecting the Heart Long-Term
Once the immediate crisis is managed, the goals shift toward preventing two things: another heart attack and the gradual weakening of the heart muscle. After a significant infarction, the damaged area can stretch and thin out over weeks and months, a process called ventricular remodeling. This remodeling is one of the main ways a heart attack leads to heart failure down the road.
Beta-blockers are a cornerstone of post-ACS therapy precisely because they counter this process. A meta-analysis of randomized trials found that beta-blockers reduce reinfarction rates, limit the size of the damaged area, suppress dangerous heart rhythms, and slow ventricular remodeling. Other medications that block hormonal pathways involved in remodeling are also started before discharge to give the heart the best chance of maintaining its pumping strength.
Cholesterol management becomes critical as well. Patients with ACS are considered very high risk for future cardiovascular events, and aggressive lowering of LDL cholesterol (the “bad” cholesterol) with high-intensity statin therapy is standard. The goal is to shrink and stabilize the fatty plaques in the arteries so they’re less likely to rupture and trigger another clot.
Cardiac Rehabilitation and Readmission Risk
What happens after the hospital stay matters enormously. Cardiac rehabilitation, a structured program of supervised exercise, education, and lifestyle coaching, is one of the most effective interventions available. Patients who complete cardiac rehab after ACS see a 26% reduction in death from heart disease, a 31% reduction in hospital readmissions within the first year, and up to a 34% lower risk of dying from any cause over five years. One large study found even stronger numbers: a 46% reduction in ACS recurrence and a 35% drop in overall mortality.
Despite these striking benefits, participation rates remain low globally. Many patients are never referred, or they start the program but don’t finish. For those who do complete it, the combination of improved fitness, better medication adherence, and sustained lifestyle changes creates a compounding protective effect that extends well beyond the program itself.